Shenzhen Kangtai Biological Products Balance Sheet Health
Financial Health criteria checks 5/6
Shenzhen Kangtai Biological Products has a total shareholder equity of CN¥9.7B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 21.8%. Its total assets and total liabilities are CN¥14.5B and CN¥4.8B respectively. Shenzhen Kangtai Biological Products's EBIT is CN¥370.1M making its interest coverage ratio 20.9. It has cash and short-term investments of CN¥310.7M.
Key information
21.8%
Debt to equity ratio
CN¥2.12b
Debt
| Interest coverage ratio | 20.9x |
| Cash | CN¥310.71m |
| Equity | CN¥9.71b |
| Total liabilities | CN¥4.81b |
| Total assets | CN¥14.52b |
Recent financial health updates
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25
Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly
May 25Recent updates
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%
Oct 13Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden
Sep 25These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts
Sep 02Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up
Aug 13Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly
May 25Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations
May 03Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%
May 01Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion
Feb 27Financial Position Analysis
Short Term Liabilities: 300601's short term assets (CN¥5.9B) exceed its short term liabilities (CN¥2.6B).
Long Term Liabilities: 300601's short term assets (CN¥5.9B) exceed its long term liabilities (CN¥2.2B).
Debt to Equity History and Analysis
Debt Level: 300601's net debt to equity ratio (18.6%) is considered satisfactory.
Reducing Debt: 300601's debt to equity ratio has increased from 10.7% to 21.8% over the past 5 years.
Debt Coverage: 300601's debt is well covered by operating cash flow (30.4%).
Interest Coverage: 300601's interest payments on its debt are well covered by EBIT (20.9x coverage).